Core Insights - LAVA Therapeutics is advancing its Gammabody® platform, focusing on bispecific gamma delta T cell engagers for cancer treatment, with significant updates expected in 2024 [2][12] Pipeline Developments - LAVA-1207 is in Phase 1/2a trials targeting metastatic castration-resistant prostate cancer (mCRPC), with a combination arm with pembrolizumab set to begin in Q2 2024 [3][5] - Pfizer's PF-08046052 is in Phase 1, representing a potential first-in-class therapy for solid tumors, with a $7 million milestone achieved in March 2024 [5][9] - LAVA-1266 is on track for an Investigational New Drug (IND) submission in Q2 2024, aimed at treating hematological malignancies [3][5] Financial Performance - As of March 31, 2024, LAVA reported cash and investments totaling $94.6 million, a slight decrease from $95.6 million at the end of 2023, providing a runway into 2026 [4][7] - Revenue for Q1 2024 was $7.0 million, a significant increase from $1.2 million in Q1 2023, primarily due to a milestone payment from Pfizer [9][10] - Operating loss for Q1 2024 was $1.95 million, a substantial improvement compared to a loss of $13.54 million in Q1 2023 [8][9] Operational Highlights - The company has successfully implemented step dosing in the LAVA-1207 trial, resulting in no ≥ Grade 2 Cytokine Release Syndrome (CRS) events reported since the change [2][6] - The company is evaluating the combination of LAVA-1207 with low dose IL-2 to enhance treatment efficacy [6][12]

TABLE OF CONTENTS SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS Page | PART I | | | | | --- | --- | --- | --- | | Item 1. | | Identity of Directors, Senior Management and Advisors | 4 | | Item 2. | | Offer Statistics and Expected Timetable | 4 | | Item 3. | | Key Information | 4 | | Item 4. | | Information on the Company | 58 | | | Item 4A. | Unresolved Staff Comments | 86 | | Item 5. | | Operating and Financial Review and Prospects | 86 | | Item 6. | | Directors, Senior Management and Employees | 95 | ...

Exhibit 99.1 Legal Disclosure: Forward-looking Statements This presentation contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this presentatic use of forward-looking words such as "anticipate," "believe," "could," "expect," "should," "plan," "intend," "estimate" and "potential," and similar terms an statements appear in a number of places in this presentation and include, but are not limited to, statements regarding our intent, belief or curr ...

Table of Contents As filed with the Securities and Exchange Commission on April 11, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For t ...

Legal Disclosure: Forward-looking Statements Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this presentation, the events and circumstances reflected in our forward-looking statements may not be ...

CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND REPLACED WITH "[***]" BECAUSE IT IS NOT MATERIAL AND IS INFORMATION THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. Exhibit 10.1 AND LAVA THERAPEUTICS N.V. SEPTEMBER 23, 2022 ERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED CED WITH "[***]" BECAUSE IT IS NOT MATERIAL AND IS INFORMATION THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. Exhibit 10.1 TABLE OF CONTENTS Page | | ARTICLE 1 DEFINITIONS & INTERPRETATION . | ...

Table of Contents As filed with the Securities and Exchange Commission on March 24, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For t ...